Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis

被引:13
作者
Duong, Nikki K. [1 ,2 ]
Shrestha, Shreesh [1 ,2 ]
Park, Dan [1 ,2 ]
Shahab, Omer [1 ,2 ]
Fagan, Andrew [1 ,2 ]
Malpaya, Zenaida [1 ,2 ]
Gallagher, Mary L. [1 ,2 ]
Morris, April [1 ,2 ]
Davis, Brian C. [1 ,2 ]
Bajaj, Jasmohan S. [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Richmond, VA 23284 USA
[2] Cent Virginia Vet Healthcare Syst, Richmond, VA 23249 USA
关键词
FORM SCALE; LACTULOSE;
D O I
10.14309/ajg.0000000000001550
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: Bowel movement (BM) frequency is used to titrate lactulose for hepatic encephalopathy (HE). However, stool consistency using the Bristol stool scale (BSS, 0-7) is often ignored. METHODS: The study included pre-BSS and post-BSS cohorts. BSS was incorporated into decision-making after training in outpatients with cirrhosis. Two to 3 BMs/d and BSS 3-4 were considered normal, whereas the rest were considered high or low; concordance between the metrics was evaluated. Medication changes and 6-month admissions were compared between this group (post-BSS) and a comparable previous group (pre-BSS). Concordance and regression analyses for all-cause admissions and H E-related admissions were performed, and comparisons were made for HE-related medication stability. In the longitudinal analysis, an outpatient group seen twice was analyzed for BSS and BMs. RESULTS: In the post-BSS cohort, 112 patients were included with only 46% BSS and BMs concordance and modest BSS/BMs correlation (r = 0.27, P = 0.005). Compared with a pre-BSS cohort (N = 114), there was a lower 6-month total (4% vs 0.36%, P< 0.001) or HE-related admission (1% vs 0.12%, P= 0.002). Regression showed model for end-stage liver disease (odds ratio [OR]: 1.10, P= 0.003) and pre-BSS/post-BSS (OR: 0.04, P< 0.001) for all-cause admissions and HE (OR: 3.59, P= 0.04) and preera/postera (OR: 0.16, P = 0.02) for HE-related admissions as significant. HE medication regimens were more stable post-BSS vs pre-BSS (32% vs 20%, P = 0.04), which was due to patients with BSS > BMs (P= 0.02). In the longitudinal analysis, 33 patients without medication changes or underlying clinical status changes were tested 36 +/- 24 days apart. No changes in BSS (P = 0.73) or BMs (P = 0.19) were found. DISCUSSION: BSS is complementary and additive to BM frequency, can modulate the risk of readmissions and stabilize HE-related therapy changes in outpatients with cirrhosis, and could help personalize HE management.
引用
收藏
页码:295 / 300
页数:6
相关论文
共 23 条
[1]   Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients [J].
Bajaj, J. S. ;
Sanyal, A. J. ;
Bell, D. ;
Gilles, H. ;
Heuman, D. M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (09) :1012-1017
[2]   Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus [J].
Bajaj, Jasmohan S. ;
Lauridsen, Mette ;
Tapper, Elliot B. ;
Duarte-Rojo, Andres ;
Rahimi, Robert S. ;
Tandon, Puneeta ;
Shawcross, Debbie L. ;
Thabut, Dominique ;
Dhiman, Radha K. ;
Romero-Gomez, Manuel ;
Sharma, Barjesh C. ;
Montagnese, Sara .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (07) :989-1002
[3]   The 3-Month Readmission Rate Remains Unacceptably High in a Large North American Cohort of Patients With Cirrhosis [J].
Bajaj, Jasmohan S. ;
Reddy, K. Rajender ;
Tandon, Puneeta ;
Wong, Florence ;
Kamath, Patrick S. ;
Garcia-Tsao, Guadalupe ;
Maliakkal, Benedict ;
Biggins, Scott W. ;
Thuluvath, Paul J. ;
Fallon, Michael B. ;
Subramanian, Ram M. ;
Vargas, Hugo ;
Thacker, Leroy R. ;
O'Leary, Jacqueline G. .
HEPATOLOGY, 2016, 64 (01) :200-208
[4]   Testing for minimal hepatic encephalopathy in the United States: An AASLD survey [J].
Bajaj, Jasmohan Singh ;
Etemadian, Ashkan ;
Hafeezullah, Muhammad ;
Saeian, Kia .
HEPATOLOGY, 2007, 45 (03) :833-834
[5]   Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome [J].
Blake, M. R. ;
Raker, J. M. ;
Whelan, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (07) :693-703
[6]   The Animal Naming Test: An Easy Tool for the Assessment of Hepatic Encephalopathy [J].
Campagna, Francesca ;
Montagnese, Sara ;
Ridola, Lorenzo ;
Senzolo, Marco ;
Schiff, Sami ;
De Rui, Michele ;
Pasquale, Chiara ;
Nardelli, Silvia ;
Pentassuglio, Ilaria ;
Merkel, Carlo ;
Angeli, Paolo ;
Riggio, Oliviero ;
Amodio, Piero .
HEPATOLOGY, 2017, 66 (01) :198-208
[7]   The Bristol Stool Scale and Its Relationship to Clostridium difficile Infection [J].
Caroff, Daniel A. ;
Edelstein, Paul H. ;
Hamilton, Keith ;
Pegues, David A. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (09) :3437-3439
[8]   Use of Lactulose in Hepatic Encephalopathy: Is It Time to Shift Targets? Reply [J].
DUONG, N. I. K. K. I. K. ;
HEUMAN, D. O. U. G. L. A. S. M. ;
BAJAJ, J. A. S. M. O. H. A. N. S. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) :E1221-E1221
[9]   Bowel Movement Frequency Is Not Linked With Cognitive Function in Cirrhosis [J].
Duong, Nikki ;
Reuter, Bradley ;
Saraireh, Hamzeh ;
Nadhem, Omar ;
Acharya, Chathur ;
Fagan, Andrew ;
Hassouneh, Ramzi ;
Bajaj, Jasmohan S. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (04) :e897-e901
[10]   Is treating the gut microbiome the key to achieving better outcomes in cirrhosis? [J].
Hatton, Grace ;
Shawcross, Debbie L. .
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (01) :1-2